GENPRONEX INC.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
GENPRONEX INC. Rapid Nucleic Acid Amplification Technology is a next-generation revolutionary nucleic acid molecular detection technology that does not require a thermal cycler and can perform nucleic acid molecular amplification reactions under isothermal conditions. GENPRONEX INC. Rapid Nucleic Acid Amplification Technology combines the advantages of speed, portability, high sensitivity, and high specificity, making it applicable to any testing environment. Furthermore, it does not require a specialized laboratory environment, expensive instruments, or specifically trained professional personnel, allowing nucleic acid molecular testing to be easily performed on-site. It is a next-generation powerful tool for Point-of-Care Testing (POCT).
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2014
Unified Business No.
24564957
Status
Active
Number of Employees
0
Total Paid-in
Capital
10,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
GENPRONEX INC. possesses a professional research and development team in molecular detection technology and has an industry-academia collaboration relationship with Chang Gung University. The main technologies and products of GENPRONEX INC. are isothermal nucleic acid amplification technology and patented molecular chip technology with simple visual interpretation. Personalized medicine and point-of-care testing (POCT) are the future trends in the development of laboratory medicine. GENPRONEX INC. is committed to the research, development, and production of "molecular diagnostic reagents and detection platforms" that can be used for rapid testing. By combining next-generation isothermal nucleic acid amplification technology with microarray molecular chip technology, the company has developed brand-new rapid molecular detection reagents and technology platforms that can be applied to various fields such as biotechnology and medicine, animal and plant quarantine, and environmental monitoring.
(The content above was translated by AI.)
(The content above was translated by AI.)
